U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022
Doses to be donated to approximately .
U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022Doses to be donated to approximately 100 low- and lower middle-income countries including
U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX FacilityEffort is part of the companies’ recent pledge of two billi.
Date Time
Share
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of Pfizer-BioNTech COVID-19 Vaccine
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.